Department of Anesthesiology, Tokushima University Hospital, 3-18-15 Kuramoto, Tokushima 770-8503, Japan.
Anesth Analg. 2011 Dec;113(6):1374-80. doi: 10.1213/ANE.0b013e3182321142. Epub 2011 Oct 14.
We investigated the effects of the imidazoline-derived α2-adrenoceptor agonist clonidine on vascular adenosine triphosphate-sensitive potassium (K(ATP)) channel activity in rat vascular smooth muscle cells and recombinant vascular K(ATP) channels transiently expressed in COS-7 cells.
Using the patch-clamp method, we investigated the effects of clonidine on the following: (1) native vascular K(ATP) channels; (2) recombinant K(ATP) channels with different combinations of various types of inwardly rectifying potassium channel (Kir6.0 family: Kir6.1, 6.2) and sulfonylurea receptor (SUR1, 2A, 2B) subunits; (3) SUR-deficient channels derived from a truncated isoform of the Kir6.2 subunit (Kir6.2ΔC36 channels); and (4) mutant Kir6.2ΔC36 channels with diminished sensitivity to ATP (Kir6.2ΔC36-K185Q channels).
Clonidine (≥3 × 10(-8) M) inhibited native K(ATP) channel activity in cell-attached configurations with a half-maximal inhibitory concentration value of 1.21 × 10(-6) M and in inside-out configurations with a half-maximal inhibitory concentration value of 0.89 × 10(-6) M. With similar potency, clonidine (10(-6) or 10(-3) M) also inhibited the activities of various recombinant SUR/Kir6.0 K(ATP) channels, the Kir6.2ΔC36 channel, and the Kir6.2ΔC36-K185Q channel.
Clinically relevant concentrations of clonidine inhibit K(ATP) channel activity in vascular smooth muscle cells. This inhibition seems to be the result of its effect on the Kir6.0 subunit and not on the SUR subunit.
我们研究了咪唑啉衍生的α2-肾上腺素受体激动剂可乐定对大鼠血管平滑肌细胞中血管三磷酸腺苷敏感性钾(K(ATP))通道活性和在 COS-7 细胞中瞬时表达的重组血管 K(ATP)通道的影响。
使用膜片钳技术,我们研究了可乐定对以下方面的影响:(1)天然血管 K(ATP)通道;(2)具有不同组合的各种内向整流钾通道(Kir6.0 家族:Kir6.1、6.2)和磺酰脲受体(SUR1、2A、2B)亚单位的重组 K(ATP)通道;(3)源自 Kir6.2 亚单位截断同工型的 SUR 缺失通道(Kir6.2ΔC36 通道);和(4)对 ATP 敏感性降低的突变 Kir6.2ΔC36 通道(Kir6.2ΔC36-K185Q 通道)。
可乐定(≥3×10(-8) M)抑制细胞附着构型中的天然 K(ATP)通道活性,半数抑制浓度值为 1.21×10(-6) M,以及在内外构型中的半数抑制浓度值为 0.89×10(-6) M。可乐定(10(-6) 或 10(-3) M)以相似的效力也抑制了各种重组 SUR/Kir6.0 K(ATP)通道、Kir6.2ΔC36 通道和 Kir6.2ΔC36-K185Q 通道的活性。
临床相关浓度的可乐定抑制血管平滑肌细胞中的 K(ATP)通道活性。这种抑制似乎是其对 Kir6.0 亚基而不是 SUR 亚基的作用的结果。